Best in Biotech 7 Nov 2023 Eight biotech companies tackling infectious diseases head-on …designation from the EMA, the company looks to submit its candidate for regulatory approval next year. Moreover, Bavarian Nordic has other vaccine candidates in the mix. MVA-BN WEV is being… November 7, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 May 2024 Eight monoclonal antibody biotechs making strides in the clinic …is a monoclonal antibody that works by binding to TIGIT, which could activate the immune system to attack cancer cells. Typically, a fragment crystallizable (Fc) region in a monoclonal antibody,… May 2, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Feb 2026 Nine biotech companies that could revolutionize obesity treatments …$1 billion to enhance its pipeline, particularly its obesity candidates, in 2024. Viking Therapeutics Headquarters: U.S.A Technology: GLP-1 and GIP receptor agonists Lead candidate: VK2735 California-based Viking Therapeutics’ weight loss… February 3, 2026 - 13 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates …jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint development of bispecific cancer antibodies… August 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Aug 2025 Five biotech companies in South Korea you should know about …bind to targets. The most advanced antibody in IMBiologics’ roster is IMB-101, which hit the clinic two months ago. It is a bispecific antibody targeting OX40L and TNF, which modulates both… August 26, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Jul 2025 14 biotech companies to know in the Boston area in 2025 …antibody-based therapies that reprogram the tumor microenvironment to improve the immune system’s ability to fight cancer. Its lead candidate, PRTH‑101, is a monoclonal antibody that targets DDR1, a collagen-binding receptor… July 4, 2025 - 15 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Oxford BioTherapeutics enters into antibody agreement with Genmab …conjugate (ADC) based therapies designed to fulfill major unmet patient needs in cancer therapeutics. These include bispecific, chimeric antigen receptor T-cell (CAR-T), Antibody Drug Conjugate (ADC) and Antibody Dependent Cell-mediated… October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Weekly Roundup 15 Dec 2023 Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered …Squibb to collaborate to develop cancer treatment Antibody therapy company SystImmune is collaborating with Bristol Myers Squibb (BMS) to develop and commercialize BL-B01D1, a bispecific antibody-drug conjugate (ADC). The candidate… December 15, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Nov 2025 11 neuroscience biotech companies you should know about …and failed to develop successful candidates. Just in the last year, there have been several notable failures in the field of candidates that once seemed to hold promise. For example,… November 25, 2025 - 16 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Feb 2020 Meet 20 European Immuno-Oncology Companies that are Fighting Cancer …very few European biotechs valued at over €1B. MorphoSys develops antibody therapies for numerous conditions. The company’s lead immuno-oncology candidate tafasitamab is a humanized monoclonal antibody that targets CD19, an… February 24, 2020 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Feb 2024 Fourteen biotech companies spearheading the antibody drug conjugate industry …addition to ADRX-0706, Adcentrx is working on a second candidate in oncology indications and another candidate aimed at treating conditions in immunology. The company also entered a three-year partnership with… February 8, 2024 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Sep 2025 Navigating German biotech: 14 key players to know …and the space is competitive, but it’s worth keeping an eye on the Evotec spin-off. CatalYm Founded: 2016 Technology: Anti-GDF-15 monoclonal antibody Lead candidate: Visugromab CatalYm, a spin-out from Würzburg… September 23, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email